5:22 PM
 | 
Jun 24, 2016
 |  BC Extra  |  Company News

Takeda ends Japan deal for two Amgen candidates

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it returned its Japanese rights to fulranumab ( AMG 403) and trebananib ( AMG...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >